Kuros BiosciencesCSBTF 71 Net Current Asset Value is $1.07 as of Dec. 2025, which is 85% below its 10-year median of 7.18. GuruFocus rates CSBTF with a GF Score™ of 71/100 and a GF Value™ of $48.29 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 565 Medical Devices & Instruments companies, Kuros Biosciences ranks worse than 88.14% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Kuros Biosciences's net current asset value per share for the quarter that ended in Dec. 2025 was $1.07.
The historical rank and industry rank for Kuros Biosciences's Net Current Asset Value or its related term are showing as below:
CSBTF'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.73 Med: 7.18 Max: 38.82
Current: 21.43
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Kuros Biosciences was 38.82. The lowest was 2.73. And the median was 7.18.
CSBTF's Price-to-Net-Current-Asset-Value is ranked worse than 88.14% of 565
companies
in the Medical Devices & Instruments industry
Industry Median: 4.93
vs CSBTF: 21.43
Kuros Biosciences (OTCPK:CSBTF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Kuros Biosciences Net Current Asset Value Related Terms
Kuros Biosciences Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Kuros Biosciences's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSBTF vs ABT, SYK, MDT: Net Current Asset Value Comparison
For the Medical Devices subindustry, Kuros Biosciences's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $1.07 mean?
Kuros Biosciences (CSBTF) has a Net Current Asset Value of $1.07 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Kuros Biosciences and its competitors. This is 85% below median its historical median of 7.18. Over the past decade, Kuros Biosciences' Net Current Asset Value has ranged from 2.73 to 38.82. According to the industry distribution chart, Kuros Biosciences ranks #498 out of 565 companies in the Medical Devices & Instruments industry, placing it in the top 88.1%.
Is Kuros Biosciences' Net Current Asset Value too high?
Kuros Biosciences' current Net Current Asset Value of $1.07 is 85% below median its 10-year median of 7.18. Over the past 10 years, this metric has ranged from a low of 2.73 to a high of 38.82. The Medical Devices & Instruments industry median Net Current Asset Value is 4.93. Kuros Biosciences' value of $1.07 is 78.3% below this industry median. Based on the distribution chart, Kuros Biosciences ranks #498 out of 565 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Kuros Biosciences has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' Net Current Asset Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #498 out of 565 companies for Net Current Asset Value. This places Kuros Biosciences in the lower half of its industry. The industry median Net Current Asset Value is 4.93. Kuros Biosciences' value of $1.07 is 78.3% below this benchmark. Historically, Kuros Biosciences' own Net Current Asset Value has ranged from 2.73 to 38.82 over the past decade. While the company's 10-year median is 7.18 vs. the industry median of 4.93, Kuros Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 4.93, based on 565 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuros Biosciences's current Net Current Asset Value of $1.07 is 78.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 4.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current Net Current Asset Value is $1.07, which is 85% below median its own 10-year median of 7.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.29, compared to a current price of $22.72 — trading 53% below its estimated fair value. The current Net Current Asset Value is $1.07, which is 85% below median its 10-year median of 7.18 and 78.3% below the Medical Devices & Instruments industry median of 4.93. Kuros Biosciences' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current Net Current Asset Value is $1.07 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $22.72 is trading 53% below its estimated GF Value™ of $48.29.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
Net Current Asset Value: $1.07 (85% below median its 10-year median of 7.18)
GF Value™: $48.29 vs. price of $22.72 (53% below fair value)
Industry Position: 78.3% below the Medical Devices & Instruments median (#498 of 565)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
71GF Score
Get the complete analysis for CSBTF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
